SLC5A2 and chronic kidney disease: The rationale for combining SGLT2 inhibitors, MRAs, GLP-1RAs, and potentially ERAs may gain support with promising data suggesting that such combinations can significantly slow CKD progression and reduce cardiovascular risk.